Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 11/20 | 0.43 |
| ▸ | PAK4 | O96013 | 9/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068873 | 0.75 | PIK3CD (0.41) | PLK4PAK4FGFR1MEN1HTT | |
| SCHEMBL4167995 | 0.74 | TGFBR1 (0.43) | PLK4PAK4FGFR1AURKBMEN1 | |
| SCHEMBL13636069 | 0.71 | EIF2AK2 (0.46) | PLK4PAK4AURKAAURKBMEN1 | |
| SCHEMBL13636054 | 0.70 | EIF2AK2 (0.51) | PLK4PAK4MEN1HTTKMT2A | |
| SCHEMBL13663576 | 0.67 | EIF2AK2 (0.55) | PLK4PAK4MEN1HTTKMT2A | |
| SCHEMBL5071850 | 0.67 | GRM4 (0.43) | AURKAMEN1HTTKMT2AHSD17B10 | |
| SCHEMBL12431088 | 0.66 | EIF2AK2 (0.51) | PLK4PAK4FGFR1AURKAAURKB | |
| SCHEMBL5068326 | 0.65 | KDM4E (0.40) | MEN1HTTKMT2AHSD17B10KDM4E | |
| SCHEMBL12430658 | 0.65 | AURKA (0.72) | PLK4PAK4AURKAAURKB | |
| SCHEMBL23889314 | 0.62 | PLK4 (0.75) | PLK4PAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-20 | — | — | US | claimed |
| EP-1345929-B1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2006-05-17 | — | — | EP | claimed |
| US-20040157893-A1 | Pyrazole compounds useful as protein kinase inhibitors | BEBBINGTON DAVID (GB) | 2004-08-12 | — | — | US | claimed |
| US-20030004164-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-01-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004164-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PLK4 157/4885PAK4 365/4885FGFR1 1042/4885 |
| US-20080287444-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, CDK3 | PLK4 120/4885PAK4 496/4885FGFR1 1039/4885 |
| US-20040157893-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PLK4 166/4885PAK4 454/4885FGFR1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.